SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001104659-22-004497
Filing Date
2022-01-14
Accepted
2022-01-14 17:21:49
Documents
13
Period of Report
2022-01-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A tm222963d1_8ka.htm   iXBRL 8-K/A 30864
2 EXHIBIT 99.1 tm222963d1_ex99-1.htm EX-99.1 226517
  Complete submission text file 0001104659-22-004497.txt   455499

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vyne-20220112.xsd EX-101.SCH 3060
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20220112_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20220112_pre.xml EX-101.PRE 22613
7 EXTRACTED XBRL INSTANCE DOCUMENT tm222963d1_8ka_htm.xml XML 4243
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-38356 | Film No.: 22532742
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences